US Patent Issued to NEOGENE THERAPEUTICS on July 21 for "Peptide markers to track genetically engineered cells" (Dutch Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,708, issued on July 21, was assigned to NEOGENE THERAPEUTICS B.V. (Amsterdam).

"Peptide markers to track genetically engineered cells" was invented by Carsten Linnemann (Amsterdam), Thomas Kuilman (Amstelveen, Netherlands), Gavin M. Bendle (Amsterdam), Jeroen W.J. van Heijst (Amstelveen, Netherlands), Xiangjun Kong (Amsterdam) and Loek Josephus Eggermont (The Hague, Netherlands).

According to the abstract* released by the U.S. Patent & Trademark Office: "To allow control over injected genetically engineered cells, it is helpful that the genetically engineered cells express a marker that can be used to detect such cells among a pool of unmodified cells. Some embodiments relate to ...